Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Curanex PharmaceuticalsCURX -10.63%12 Debt-to-Equity is 0.06 as of Jun. 2026, which is 20% above its 10-year median of 0.05. GuruFocus rates CURX with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 954 Biotechnology companies, Curanex Pharmaceuticals ranks better than 68.34% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Curanex Pharmaceuticals's Debt-to-Equity or its related term are showing as below:
CURX'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.05 Max: 1.56
Current: 0.06
During the past 4 years, the highest Debt-to-Equity Ratio of Curanex Pharmaceuticals was 1.56. The lowest was 0.00. And the median was 0.05.
CURX's Debt-to-Equity is ranked better than 68.34% of 954
companies
in the Biotechnology industry
Industry Median: 0.16
vs CURX: 0.06
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Curanex Pharmaceuticals Debt-to-Equity Related Terms
Curanex Pharmaceuticals Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CURX vs DRMA, NCNA, CELZ: Debt-to-Equity Comparison
For the Biotechnology subindustry, Curanex Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Curanex Pharmaceuticals Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Curanex Pharmaceuticals's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Curanex Pharmaceuticals's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Curanex Pharmaceuticals (CURX) has a Debt-to-Equity of 0.06 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Curanex Pharmaceuticals and its competitors. This is 20% above median its historical median of 0.05. According to the industry distribution chart, Curanex Pharmaceuticals ranks #302 out of 954 companies in the Biotechnology industry, placing it in the top 31.7%.
Is Curanex Pharmaceuticals' Debt-to-Equity too high?
Curanex Pharmaceuticals' current Debt-to-Equity of 0.06 is 20% above median its 10-year median of 0.05. The Biotechnology industry median Debt-to-Equity is 0.16. Curanex Pharmaceuticals' value of 0.06 is 62.5% below this industry median. Based on the distribution chart, Curanex Pharmaceuticals ranks #302 out of 954 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Curanex Pharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Curanex Pharmaceuticals' Debt-to-Equity compare to DRMA and NCNA?
According to the Biotechnology industry distribution chart, Curanex Pharmaceuticals ranks #302 out of 954 companies for Debt-to-Equity. This puts Curanex Pharmaceuticals in the upper half of its industry. The industry median Debt-to-Equity is 0.16. Curanex Pharmaceuticals' value of 0.06 is 62.5% below this benchmark. While the company's 10-year median is 0.05 vs. the industry median of 0.16, Curanex Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 954 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Curanex Pharmaceuticals's current Debt-to-Equity of 0.06 is 62.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Curanex Pharmaceuticals and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Curanex Pharmaceuticals's current Debt-to-Equity is 0.06, which is 20% above median its own 10-year median of 0.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curanex Pharmaceuticals stock overvalued right now?
Curanex Pharmaceuticals (CURX) has a current Debt-to-Equity of 0.06. The current Debt-to-Equity is 0.06, which is 20% above median its 10-year median of 0.05 and 62.5% below the Biotechnology industry median of 0.16. Curanex Pharmaceuticals' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Curanex Pharmaceuticals (CURX), the current Debt-to-Equity is 0.06 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout. Phyto-N, is a proprietary botanical extract with chemical components and pharmacological activities that harnesses potential anti-inflammatory properties of a medicinal plant.
12GF Score
Get the complete analysis for CURX
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CURX has been successfully added to your 
